GlassScriptPhysician profile
Andrew S Cole
NPI 1699901611
$2,630.05
in general payments reported to CMS, 2019-2025
26 companies · $965 in 2025
The $965 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.98 · 2020: $67.06 · 2021: $58.19 · 2022: $324 · 2023: $433 · 2024: $711 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,329.83 | 2020-2025 | Botox, Qulipta, Ubrelvy |
| Nevro Corp. | $171.83 | 2024 | Senza |
| Medtronic, INC. | $159.73 | 2021-2025 | Synchromedii |
| Braeburn INC. | $120.21 | 2025 | Brixadi |
| Allergan, INC. | $103.05 | 2019-2022 | |
| Abbott Laboratories | $95.07 | 2023 | Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.19 | 2022-2024 | Ofev, Jardiance |
| Otsuka America Pharmaceutical, INC. | $58.57 | 2024-2025 | Rexulti |
| Amgen INC. | $57.68 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.93 | 2023-2025 | Farxiga |
| Pfizer INC. | $48.89 | 2025 | |
| Alkermes, INC. | $41.31 | 2022-2024 | Vivitrol |
| Saol Therapeutics INC. | $31.98 | 2019 | |
| Novo Nordisk INC | $29.37 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $24.62 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.27 | 2025 | Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.42 | 2025 | Caplyta |
| Indivior INC. | $23.18 | 2024 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $23.00 | 2025 | Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $22.64 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.45 | 2024 | |
| Merz Pharmaceuticals, LLC | $16.50 | 2025 | Xeomin |
| Mylan Specialty L.P. | $16.23 | 2022 | |
| Lilly USA, LLC | $14.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.27 | 2023 | Camzyos |
| Glaxosmithkline, LLC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.